
Gate to Omics

- General concept of proteOmics and more!



병리학교실 조 남훈



Contents

- 1. Design of study
- 2. Phenomics
- 3. Proteomics principle
- 4. Clinical application of display proteomics
- 4. Tissue MALDI-imaging MS and application
- 5. Rho family and cancer
- 6. Conclusion and message


Project Overview [1]

- With What
 - In vitro: cell line으로 실험관 배양
 - Ex vivo: primary culture 후 동물에 재이식
 - In vivo: mouse injection으로 채내실험
 - Human: 인체 시료 조직등 이용한 실험
- By What
 - DNA: regulation, mutation
 - RNA: transcription, regulation, expression
 - Protein: interaction, function, expression
 - Epigenetic: posttranslational modification

Project Overview [II]

How

- Screening
 - DNA array/chip/array CGH
 - cDNA array/RT-PCR-based array
 - Proteomics/protein chip
 - Phosphoproteomics/Methylation chip
- Targeting
 - PCR-based blot/ ISH
 - RT-PCR-based blot/RT-ISH
 - Blotting/immuno-based IF/IHC




Nature Reviews | Drug Discovery


Functional

- Kinetic assay
- Interaction Affinity assay: Chip/FRET/IP/co-IP/yeast two hybrid assay
- Invasion/migration/motility assay

Project Overview [III]

- Screening high-throughput technology; Omics
- Omics: Large scale, high-throughput process-BIT
 - Genomics
 - Post genomics/Functional genomics
 - pharmacogenomics
 - Transcriptomics
 - Proteomics
 - Metabolomics
 - Kinomics
 - Physiomics
 - Nutrinomics
 - Epigenomics
 - Clinomics : Application
 - Phenomics (?) : validation






Phenomics

- Phenomics define to find and correlate the whole morphologic spectrum (from the normal to abnormal spatial concept) with 'Omics data with preservation of integral parts of cell and tissue structure
- In the narrow technical concept of phenomics, tissue microarray (TMA) is regarded as high throughput technique.
 - Limitation to overall configuration
 - Accurate knowledge of tissue morphology
 - Good clinical repository data-based well-trained TMA set
 - Standardization of interpretation algorithm
- Normal vs. abnormal (dysplasia-neoplasia)
 - Normal: phenotypically normal, but unknown gnotypic alteration
 - Diverse spectrum in normal
 - Incipient or cryptogenic or subtle or subclinical alteration
 - Gradual or abrupt transition of morphologic spectrum
 - Tissue specificity a/w microenvironment
- Finish line of Omics and New Start line of Fused Omics

Examples of Phenomics

- Screening purpose
 - From brain to toe
 - For a new molecule specificity/sensitivity evaluation
- Organotypic cancer TMA
 - according to pT/pN/pM
 - according to cell/histologic type
 - m/c used
- Specific zone TMA
 - Collection of intraepithelial neoplasia
 - Sorting to atypia zone
 - Capsule/margin zone
 - Vigorous necrosis d/t iatrogenic regression



Limitation

- Tissue ischemia times (intra— and postsurgical)
 Following tumor resection, approx. 25-30% of proteins and 20-25% of genes are differentially expressed within the first 30 minutes.
- Spatial heterogeneity (periphery vs. epicenter)
- Angiogeneis model
- Average index model (Ki67....)
- EMT model (focal patch expression)
- TME model (surrounding stroma)

Websites useful

- http://www.genecards.org (무료)
 - Overall survey for specific gene
- http://www.ingenuity.com/index.html (유료)
 - Gene map networks
- http://cmbi.bjmu.edu.cn/transmir (무료)
 - miRNA-TF network

Short-cut to a thesis [III] -Order of writing-

1. Goal (introduction)

Think always before

2. Materials

Note at the bench

3. Methods

Note at the bench

4. Results

Note at the bench

5. Discussion

Never touch before

6. References

With discussion

7. Introduction

After discussion

8. Abstract

Summary of Final message

9. Title

Shorter Precis

Proteomics 원리 및 응용

조 남훈

연세의대 병리학교실

Proteome Effect

- 1970-1990 Human Genome project
- 1990년 이후 postgenome era
- 1995년 proteome 탄생
- Functional genomics
 - Posttranslational modification
 - One gene-multiple proteins
- Subcellular profiling
 - Shuttling or movement
- Integrated dogma
 - Approach to final conclusion

Proteome 구분

- Expression (display) proteomics
 - Disease-specific expression
 - Biomarker discovery
 - Drug action of mechanism
 - Drug candidate
- Cell-map proteomics
 - Molecular pathophysiology
 - Proteomics in situ MS

mRNA-protein관계

- Genome-mRNA 전사단계에서 coding sequence선택 변수
- mRNA-protein 번역단계에서 변형과정
- 번역후 변형과정 (post-translational modification)
 - (de)phospholy, (de)glycosyl, (de)acetylation
- 60 cell lines glutathion S-transferase mRNA-protein expression 出교 (*k*=0.43) Tew, et al., Mol Pharmacol 50:149, 1996

Step for proteomics

- 1. Protein preparation
- 2. Protein separation
- 3. Image analysis
- 4. Protein excision
- 5. Mass spectrophotometry
- 6. Protein identification
- 7. Protein validation

Protein Preparation



Rule of thumb: minimize freeze-thaw cycle

- Fresh serum
 - aliquot to 4 tubes, each 25 µL, centrifuge, supernatant into 0.5 µL alliquot, and frozen
- 2. Body fluids avoid pink or red sample for hemolysis
- 3. Biopsy tissues
 - avoid formalin, if not, rinsing with saline, mincing with a clean razor blade into pieces (less than 0.5 cm or 50 mg), and immediately frozen
- 4. Urine: low concentration and salt/urea
 - 10mL tube alliquot- 10mL Acetone precipitaiton or ultracentrifugation (200,000g for 120min at 4°C)

Protein Separation

- 1st EP: pI 분류 (net charge)
- 2nd EP: MW분류 (SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis)
- 2D-GE: cornerstone of proteome study
- Limitation of 2D-GE:
 - Membrane proteins
 - Too large or small proteins
 - Highly basic or acidic proteins
- Strategies for shortcoming
 - Fractionation by ion-exchange chromatography
 - Affinity chromatography
 - Subcellular fractionation
 - 1D and subsequent high performance liquid chromatography (HPLC)
- 염색

```
Coomassie brilliant blue staining (detection limit > 100ng)
Silver staining (detection limit > 1~2ng)
SYPRO RUBY
```





Image analysis

- Imaging system
 - Densitometry analysis
- Software analysis
 - PDQuest (100 gel image동시 분석)
 - MELANIE, IMAGE MASTER, HERMes, GELLABE
- Protein DB comparative analysis
 - SWISS-2D db
 - Molecular/medical/scientific knowledge support




PDQuest 62 66 70 74 78 82 9.0 150.0 100.0 90.0 80.0 70.0 60.0 50.0 40.0 $\mathsf{Mr}_{30.0}$ 0020 20.0 ~1010 2002 20073002

> 900 jon 1919 4.8

4.4

15.0

Protein Excision



Mass Definitions

- Molecular masses are measured in Daltons (Da) or mass units (u). Dalton is defined as 1/12 of the mass of a ¹²C atom. Relative molecular mass (Mr) is unitless because it is a ratio. Mass-to-charge ratio (m/z) is often used as the abscissa in a mass spectrum because a mass spectrometer separates ions on this basis.
- "Average mass" is calculated by summing the weighted average masses ("atomic weights") of the constituent atoms. The result is a weighted average over all of the naturally occurring isotopes present in the compound. This is the common chemical molecular weight that is used for stoichiometric calculations (H =1.0080, C = 12.011, O= 15.994, etc.). The mass cannot be calculated as accurately as the monoisotopic mass because of variations in natural isotopic abundances.
- "Monoisotopic mass" is calculated by summing the exact masses of the most abundant isotope of each element present, i.e., ${}^{1}H = 1.007825$, ${}^{12}C = 12.000000$ (by definition), ${}^{16}O = 15.994915$, etc. This is the most accurately defined molecular mass and is preferred if a measurement can be made with sufficient resolution.

MALDI-TOF 질량분석기

- <u>Matrix Assisted Laser Desorption Ionization</u>
- <u>Time Of Flight Mass Spectrometry</u>







Voyager DE-STR

Voyager DE-Pro

질량분석기의 구성




Matrix-Assisted Laser Desorption Ionization (MALDI)



In Matrix-Assisted Laser Desortion Ionization (MALDI), sample is embedded in a low molecular weight, UV-adsorbing matrix that enhances intact desorption and ionization of the sample. The matrix is present in vast excess of sample, and therefore isolates individual sample molecules.

Linear TOF에서 분자 이온들의 분리


Flight Tube (0.5 - 4m)



가벼운 이온들은 무거운 이온들보다 먼저 검출기에 도착한다.

이 비행시간(time of flight)은 질량으로 다음 식에 의해 변환된다 (KE=1/2mv²).

Reflector TOF내 분자이온의 비행



- 주어진 진공상태의 비행관 (tube) 내에서 이온이 비행할 수 있는 거리를 길게 해주어 분리능(resolution)을 향상 되는 디자인
- Peptide등의 정확한 질량 분석이 필요한 Proteomics 응용에 적합함
- Reflector (ion mirror)를 비행관의 끝에 설치하여 이온 비행 방향을 바꾸어 주고 또 하나의 검출기(detector) 를 반대편에 설치함.
- 이 디자인의 장비로는 응용에 따라 Linear 또는 Reflector 모드로 사용함

Matrix 종류

Matrix 종류	<u> </u>			
Sinapinic Acid	Proteins >10kDa			
α -Cyano-4-hydroxy-cinnamic acid (CHCA)	Peptides<10kDa			
2,5-Dihydroxybenzoic acid (DHB)	Neutral Carbohydrates, synthetic polymers			
Super DHB	Proteins, Glycosylated proteins			
3-Hydroxypicolinic acid	Oligonucleotides			
HABA	Proteins, Oligosaccharides			
CH=C(CN)COOH	OH CH ₃ O CH=CHCOOH			

α-cyano-4-hydroxycinnamic acid

2,5-dihydroxybenzoic acid (2,5-DHB)

Sinapinic acid (3,5-Dimethoxy-4-hydroxy cinnamic acid)

Mass spectrophotometry (MS)

Peptide mass fingerprinting

- Gel상에서 원하는 단백질 spot을 찾은 다음, trypsin과 같은proteolytic enzyme을 이용하여 작은 크기의 peptide로 분해
- 이 peptide의 질량을 MALDI-TOF 질량분석계를 이용하여 측정
- 여기서 나온 결과 (m/z value)를 가지고 기존의database를 탐색하여 이들과 일치하는 peptide를 찾는방법

Peak detected


- average MW 아닌 monoisotopic MW
- Signal vs. noise구분 가능

MS/MS: tandem mass spectrometer

- 분리된 단백질들의 정체확인을 위한 다른 방법은 위에서 얻은 tryptic peptide의 아미노산 배열을 MS/MS를 이용하여 알고 일치하는 sequence를 포함하는 단백질을 db에서 찾아보는 방법

System Components

1. 시료는 *matrix* 와 혼합하여 target에 건조함 5. Ions 은 질량대 전하(mass to charge) 에 4. Ions 은 전기장에 의해 가속되어 빈관 내부로 비행함 따라 각기 다른 시간(times) 에 검출기에 도 (*f*/*y* down) 20 - 30 kV High vacuum 2. Target를 MS의 고진공 상태 내부로 도입 3. Sample spot 에 *laser* 를 발사하여, *ions* 은 기체상으로 탈착되면 시계를 시작하여 배행시간을 (time of flight) 측정



Protein Identification

Probability of Matching index with theoretical peptide database

Acc. #: P30304 Species: HUMAN Name: M-phase inducer phosphatase 1 (Dual specificity phosphatase Cdc25A)

Index: 129733 MW: 58797 Da pI: 6.3

m/z Submitted	MH+ Matched	Delta ppm	Modificati	ions Start	End	Missed Cleavages	Database Sequence
972.5135	972.5552	-43		111	119	0	(K) <u>LLGCSPALK</u> (R)
1065.4968	1065.5403	-41		378	385	0	(K) <u>EFVIIDCR</u> (Y)
1091.5472	1091.5485	-1.2		448	456	1	(R) <u>DRLGNEYPK</u> (L)
1092.5343	1092.5842	-46		343	352	0	(K) <u>GYLFHTVAGK</u> (H)
1106.5668	1106.5345	29		467	475	1	(K) <u>GGYKEFFMK</u> (C)
1521.7929	1521.7987	-3.8		358	371	0	(K) <u>YISPEIMASVLNGK</u> (F)
1534.8035	1534.7284	49		175	188	0	(R) <u>QNSAQLGMLSSNER</u> (D)
1537.7725	1537.7936	-14	1 N	Met-ox 358	371	0	(K)YISPEIMASVLNGK(F)
1705.8585	1705.8873	-17		307	322	0	(K) <u>AHETLHQSLSLASSPK</u> (G)
1778.8241	1778.9012	-43		423	436	1	(K) <u>RVIVVFHCEFSSER</u> (G)
2224.1046	2224.2052	-45	1 N	Met-ox 358	377	1	(K)YISPEIMASVLNGKFANLIK(E)
2232.2191	2232.1148	47		323	342	1	(K) <u>GTIENILDNDPRDLIGDFSK</u> (G)

Protein Identification


Probability of Matching index with theoretical peptide database

Spot Number	Candidate	MOWSE Score	Cov(%)	Protein MW(Da/pl)	Acession #
1123	ZW10 interactor (ZW10 interacting protein-1)	5300	29	31195/5.0	095229
6123	DNA-repair protein XRCC3	1.78E+04	35	37850/8.8	O43542
6213	Mitogen-activated protein kinase 3	688	24	43136/6.3	P27361
5417	Caspase-2 precursor (CASP-2) (ICH-1 protea se)	1.59E+07	43	54040/6.2	Q16877


Validation of peptide detected


- Clustergram
 - Reverse clustergram
 - Heat map algorithm
- Distance map tree
 - Phylgenetic algorithm
- Tissue confirmation
 - WB
 - IF
 - IHC

Expression profile and its similarity analysis By clustering and profile distance calculation




Ovary ca proteomics classification






Serous and Endometrioid ca in ovary is similar in proteome





Ovary cancer proteomics classification

- *J. Proteome Res.*, 2006, *5* (5), pp 1082–1090
- Comparative Proteomics of Ovarian Epithelial Tumors
- Hee Jung An,[†] Dong Su Kim, Yong Kyu Park, Sei Kwang Kim, Yoon Pyo Choi,[§] Suki Kang,[‡] Boxiao Ding,[§] and Nam Hoon Cho**
- We analyzed 12 ovarian epithelial tumors using 2D PAGE-based comparative proteomics to construct intra- and inter-tumoral distance map trees and to discover surrogate biom arkers indicative of an ovarian tumor. The analysis was performed after laser microdissec tion of 12 fresh-frozen tissue samples, including 4 serous, 5 mucinous, and 3 endometri oid tumors, with correlation with their histopathological characteristics. Ovarian epithelia I tumors and normal tissues showed an apparent separation on the distance map tree. Mucinous carcinomas were closest to the normal group, whereas serous carcinomas were e located furthest from the normal group. All mucinous tumors with aggressive histolog y were separated from the low malignant potential (LMP) group. The benign-looking cys ts adjacent to the intraepithelial carcinoma (IEC) showed an expression pattern identical to that of the IEC area. The extent of change on the lineages leading to the mucinous a nd serous carcinoma was 1.98-fold different. The overall gene expression profiles of sero us or endometrioid carcinomas appeared to be less affected by grade or stage than by histologic type. The potential candidate biomarkers screened in ovarian tumors and found to be significantly up-regulated in comparison to normal tissues were as follows: N M23, annexin-1, protein phosphatase-1, ferritin light chain, proteasome α-6, and NAGK (N-acetyl glucosamine kinase). In conclusion, ovarian mucinous tumors are distinct from other ovarian epithelial tumors. LMP mucinous tumors showing histologically aggressive features belong to mucinous carcinoma on the proteomic basis.

Lung NECa typing Recategorization







Comparative proteomics in Lung neuroendocrine cancer

J. Proteome Res., 2006, 5 (3), pp 643-650


Comparative Proteomics of Pulmonary Tumors with Neuroendocrine Differentiation

Nam Hoon Cho,*,†,§ Eun Suk Koh,‡ Dong Wha Lee,‡ Haeryoung Kim,† Youn Pyo Choi,†,§ Sang Ho Cho,† and Dong Su Kim|


We aimed to evaluate neuroendocrine pulmonary tumors (NEPT) by a novel method involving map tree construction by comparing all of the protein spots. We performed a proteomics analysis to assess the similarities in protein expression between neuroendocrine pulmonary tumors (NEPT), including typical carcinoids (TC), atypical carcinoids (AC), large cell neuroendocrine carcinomas (LCNEC) and small cell carcinomas (SCLC). Total protein lysates were obtained from seven histologically confirmed frozen NEPT tissues, including 1TC, 2 SCLC, and 4 cases ranging from AC to LCNEC. 2-DE demonstrated that TC was similar to normal lung. AC, LCNEC, and SCLC were similar to each other, forming a group separate from TC, however, SCLC at an early stage showed a similarity to TC. MALDI analysis detected 9 surrogate endpoint biomarkers, including eIF5A1, GST M3, cytokeratin 18 (CK 18), FK506-binding protein p59, p63, MAGE-D2, mitochondrial short-chain enoyl-coenzyme A hydratase 1, tranferrin and poly (rC) binding protein 1. Immunohistochemical staining revealed a gradual decrease in expression rate of p63 and CK 18 with poor differentiation of NEPT. Our results demonstrate that (1) the comparative proteomics of NEPT match the WHO classification except for AC and LCNEC; (2) SCLC show differences in their proteomics according to tumor stage; and (3) CK 18 and p63 may be useful as diagnostically and prognostically available markers.

Example of narrow-down validation


IPA from proteomics or cDNA array in breast ca




Integrin receptor aggregation, induced by ECM interactions, stimulates signal transduction cascades




Protein network in regulation of actin-based motility by Rho. The diagram shows that a motility network including ARHGDA, WDR1, KRT8, and CAPG can be constructed through surrogate molecules in regulation of actin-based motility by Rho. These four molecules are closely linked to one another, but are not directly associated. Gray represents high upregulation and validation of protein expression of related genes by IPA analysis.



Gene 정보 찾기: http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=retrieve&dopt=full_report&list_uids=7430





Comparative proteomics in breast cancer regarding invasion

- J Proteome Res. 2010 Nov 5;9(11):5638-45.
- Proteomic molecular portrait of interface zone in breast cancer.
- <u>Kang S, Kim MJ</u>, <u>An H, Kim BG</u>, <u>Choi YP</u>, <u>Kang KS</u>, <u>Gao MQ</u>, <u>Park H</u>, <u>Na HJ</u>, <u>Kim HK</u>, <u>Yun HR</u>, Kim DS, Cho NH.

Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.

Abstract

• Surgical tumor margins are intended to encompass residual tumor cells but may not alw ays accurately delineate the boundary between tumor and normal tissue. Efforts to define tumor margins based on molecular analysis have achieved limited success. Furtherm ore, no clinical trials have addressed the scope of the tumor microenvironment. Here, we considered the tumor cell population and surrounding microenvironment in delineating tumor margins, classifying breast cancer into tumor and normal zones, and introducing the concept of an interface zone, the region between the invading tumor front and normal tissue, which develops during tumor invasion and metastasis through remodeling of the tumor microenvironment. Pathological signatures of invasion markers in tumor tiss ues are most dynamic within the invading tumor front. We compared protein profiles of tumor, normal, and interface zones using MALDI-MS. Proteins upregulated in the interface zone were identified by peptide mass fingerprinting and confirmed by database sear ching with chemically assisted MALDI-PSD spectra. Upregulation was confirmed for Rho GDIα, CAPG, WDR1, and CK8 by Western and immunohistochemical analyses. Our result s demonstrate that the molecular profile of the interface zone is unique and suggest that upregulation of proteins here may be related to progression and metastasis of breast c arcinomas.

comparative proteomics in Ut Cervical cancer in a/w HPV

REGULAR ARTICLE

Proteomic analysis of progressive factors in uterine cervical cancer Yoon Pyo Choi2, Suki Kang1, Sunghee Hong1, Xianhe Xie2 and Nam Hoon Cho2

Human papillomavirus (HPV) infections play a crucial role in the progress of cervical cancer. The high-risk HPV types are frequently associated with the development of malignant lesions. Some of the latest studies have demonstrated that the high-risk HPV 16 and 18 are predominantly detected in the more aggressive cancers. In the present study, we aimed to establish the proteomic

profiles and characterization of the tumor related proteins by using two-dimensional gel electrophoresis (2-DE) and matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS). For proteomic analysis, patients infected by HPV 16 or 18 were included in this study. We compared nuclear protein and cytoplasmic protein, separately by using the subcellular fraction. Differential protein spots between cervical cancer with high-risk HPV, HPV 16 or HPV 18, and HaCaT cell lines were characterized by 2-DE. Those proteins analyzed by peptide mass fingerprinting based on MALDI-TOF MS and database séarching were

the products of oncogenes or proto-oncogenes, and the others were involved in the regulation of cell cycle, for general genomic stability, telomerase activation, and cell immortalization. However, there was no difference in protein characterization for cervical cancer between HPV 16 and HPV 18 infection. Nonetheless, these data are valuable for the mass identification of differentially


expressed proteins involved in human uterine cervical cancer. Moreover, the data has enormous value for establishing the human uterine cervical cancer proteome database that can be used in screening a molecular marker for the further study of human uterine cervical cancer, and also for studying any correlation among the cancers induced by HPV.

Keywords:

Differential expression protein / Human uterine cervical cancer / Matrix-assisted laser desorption/ionization-time of flight mass spectrometry / Two-dimensional gel electrophoresis

MALDI-Imaging MS


MALDI-MS Image localization



1. Bruker Imaging prep.




Teflon coated spray chamber



2. Shimadzu Chip 1000





MALDI Imaging





Principle:

Acquisition of spatially resolved MALDI spectra


Intensity of specific signals is translated into colour intensity

Example Zebrafish: Resolution 200 µm Matrix Sinapinic acid





Bruker Daltonics



ImagePrep





Compact instrument with integrated touchpanel control



Teflon coated spray chamber




Spray head with matrix reservoir

17 Bruker Daltonics

ImagePrep Droplet Generation





 Soft, gravitational droplet deposition, controlled atmosphere


Tissue MALDI imaging system









Main Unit




Microscale Proteome Analysis




MALDI imaging-PMF using FFT




MALDI-tissue image correlation



Ovarian Cancer biomarker



Tissue MALDI-2D GE-PMF




Marker identification and validation

Table 1. Protein Identification of Interface Overexpression.


Spot No.	Protein name	Accession No.	PI a / PI b	MW a / MW b (K Da)	Sequence Coverage (%)	Est'Z Score	Fold IZ/N c	Fold IZ/T d
9026	PRDX 1	CAI13096	9.58/6.4	25.82/19.13	46	2.36	3.1	1.8
1619	Plastin 2	P13796	4.81/5.2	67.26/70.84	31	2.41	1.76	1.72

^{*}The peptide profiles of the protein spots treated with trypsin were analyzed by MALDI-TOF MS. ProFound (http://129.85.19.192/profound_bin/WebProFound.exe) was used to search the protein database for protein identification using peptide mass fingerprinting (PMF). The mass and pI values specified are theoretically matched by a database search. a: observed, b: theoretically calculated, c: the rate of increase in intensity (average interface sample intensity/average normal sample intensity), d: the rate of increase in intensity (average interface sample intensity/average tumor sample intensity).



Schematic representation of the MALDI-IMS technology

Step I. Application of matrix and enzymatic digestion



- Application of matrix and enzymatic digestion of proteins.
- Identification of proteins using protein database matching.
- 3) Validation of protein identities.

 Recently, identification of proteins may be directly performed from the MALDI-IMS without any analytic process of extraction and proteolysis.

Solid line, performed in the present study; **Dotted line**, not performed in the present study, but possible.

CHCA, α-Cyano-4-hydroxycinnamic acid;

DHB, 2,5-dihydroxybenzoic acid;

SA, sinapinic acid;

MS, mass spectrometry;



Technical Note

Molecular Proteomics Imaging of Tumor Interfaces by Mass Spectrometry

SUKI KANG, Hyo Sup Shim, Jong Sik Lee, Dong Su Kim, Hak Yong Kim, Seong Hyun Hong, Pan Soo Kim, Joo Heon Youn, and *Nam Hoon Cho*

J. Proteome Res., 12 October 2009


Abstract


The specific molecular profiles of ovarian cancer interface zones (IZ), the region between tumors and normal tissues, were evaluated using a new method involving matrix-assisted laser desorption/ionization (MALDI)-imaging mass spectrometry (IMS). We analyzed three ovarian serous carcinomas using MALDI-IMS. Principal component analysis (PCA) was used to evaluate the quality of tissue spatial features based on MALDI-IMS, and for analysis of large datasets of MALDI-IMS. 2-dimensional gel electrophoresis and fluorescence microscopy were used to verify interface-specific proteins. Unique profiles were identified for the tumors, the normal zone, and the IZ. Through MALDI analysis, two interface-specific proteins, plastin 2 and peroxiredoxin 1 (PRDX 1) were identified as differentially regulated between zones. Fluorescence microscopy revealed high expression levels of plastin 2 and PRDX 1 along the IZ of ovarian tumors. This comparative proteomics study using tissue MALDI-IMS, suggested that the IZ is different from the adjacent tumor and normal zones, and that plastin 2 and PRDX 1 may be interface markers specific to ovarian tumors.


Rho family in breast ca as diagnostic & prognostic markers


- Cell Motility Factors screened by proteomics in breast ca
 - Rho family: GTPase
 - ER/Her2 status correlation
 - Triple negative breast ca biomarker
 - personalized targeted therapy

Cell invasion vs. Tumor invasior









Correlation of Cell Migration and Tissue Invasion with Metastasis


- Cell biology
 - Asymmetric <u>polarized morphology</u>
 - Kinetic fluctuation in receptor-ligand binding
 - Concentration gradient- independent
 Cell migration. Cell 1996; 84:359-69 (Bible for migration)
- Tissue biology
 - Early onset of microinvasion: step-wise model
 - Diagnostic useful universal kit: BM disruption or formation, with different composition
- Clinical biology
 - TNM stage reassessment
 - Aggressive non-invasive cancer
 - Biomarker to predict invasion or metastasis

Rho-GTPases regulate actin filaments and cytoskeletal organization.


Cdc42 generally controls the cell polarity and the formation of filopodia and nascent <u>focal</u> <u>complexes</u> (shown as yellow dots).

Rho influences cell adhesion assembly and maturation, in addition to controlling stress fiber formation and contractile activity.

Rac1 primarily controls actin assembly and adhesion in the lamellipodium.





Five step of cell migration



Tumor-cell invasion and migration. Friedl & Wolf Nat Rev Cancer 2003; 3:362-74

Metastasis: transitions between epithelial and mesenchymal stat es during carcinoma progression






Tissue validation could be confirmative step for arbitrary issues in Omcis


Examples of undergoing project with arguable data in omics study


Rho-GDI in breast ca?


- up or down?
- ER interaction?
- ErbB2 interaction?
- T-stage ?
- N-stage ?
- metastasis?



Rho GDI as regulator of cell migration







Take Home Message

Omics as magic-screening tools with innumerable gems,

but should be purified to be a diamond.

All your idea make yourself innovative and inspired!

Any innovation move science one step forward!

Discipline yourself through your invention!

Be a physician scientist beyond medical skill master